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intraoperative findings, and follow-up duration. The outcomes studied
were limb salvage and primary stent patency. Continuous data were
analyzed with a t test, and categoric data were analyzed with a 2 test.
Results: We identified 40 patients in the proximal stent group and
56 in the distal stent group. Follow-up imaging data were available for 82
patients. The two groups did not differ in demographics, mean number
of patent runoff vessels (proximal, 2.0 vessels; distal, 1.8 vessels; P 
.18), or mean duration of follow-up (proximal, 259 days; distal, 257
days; P  .98). Claudication was more often an indication for popliteal
stent placement in the proximal group (42% vs 16%; P  .004). Limb-
threatening ischemia was more frequently an indication for stent place-
ment in the distal group (75% vs 55%; P  .04). Limb salvage was
achieved in 92.5% of proximal and in 85.7% of distal stent placements
(P  .30). Limb salvage did not differ between the groups when only
patients with limb-threatening ischemia were included in the analysis
(proximal, 86%; distal, 83%; P  .75). Primary patency at 3 months was
57% in the proximal group vs 49% in the distal group (P  .46).
Conclusions: Popliteal artery stenting is associated with a high rate
of limb salvage at a mean follow-up of 8 months and is an acceptable
option for patients with incapacitating claudication and limb-threatening
ischemia who are poor candidates for alternative interventions. Popliteal
stents placed across the knee joint did not affect limb salvage or patency
compared with stents placed above the knee joint.
Low Levels of High-Density Lipoproteins Are Associated With Acute
Kidney Injury Following Revascularization for Chronic Limb Ischemia
Hasan H. Dosluoglu,1,2 Pradeep Arora, MD,1,2 Nauman Tahir, MD,2
James W. Lohr, MD,1,2 Purandath Lall, MBBS,1,2 Nader D. Nader1,2. 1VA
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Objective(s): Perioperative acute kidney injury (AKI) is not uncom-
mon in patients after extremity revascularization. High-density lipopro-
teins (HDL) have been shown to reduce organ injury and death in animal
models via modulation of adhesion molecules and cytokines. Our aim was
to examine the association of HDL and other factors on perioperative
AKI in patients undergoing revascularization for symptomatic chronic
limb ischemia.
Methods: All patients who underwent open or endovascular revas-
cularization between June 2001 and December 2009 for symptomatic
chronic limb ischemia (Rutherford category 3 to 6) were retrospectively
analyzed. Patients on dialysis and those with incomplete data were
excluded. Patients were grouped for HDL 40 or 40 mg/dL. Univar-
iate and multivariate analysis were used to identify factors associated with
AKI.
Results: Included were 684 patients (219 open, 465 endovascular/
hybrid) with diabetes (47%) chronic kidney disease (20%), critical limb
ischemia (31%), and 40 HDL (60%). Medications included statin use
(57%), angiotensin converting enzyme inhibitors/angiotensin receptor
blockers (53%). Postoperative AKI developed in 85 patients (12.4%),
9.4% endovascular vs 12.6% open (P  NS). The AKI group was more
likely to be older (71.5  10.1 vs 68.0  10.8 years, P  .01), have
diabetes (60% vs 46%, P .01), be using angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers (64% vs 52%, P  .04), and
have pre-existing chronic kidney disease (36% vs 17%, P  .001). AKI
occurred in 16% of patients with low HDL and in 7% with high HDL
(P  .001). Multivariate analysis using logistic and propensity score
showed that HDL level (hazard ratio, 2.4; 95% confidence interval,
1.4-4.2) and underlying chronic kidney disease were independent pre-
dictors of postoperative AKI (P  .001).
Conclusions: AKI after revascularization is not uncommon (12.4%),
and lower HDL, along with chronic kidney disease, is associated with
increased odds of postoperative AKI. If these observations can be verified
in a prospective fashion, strategies for increasing HDL level in patients
with a high risk of postoperative AKI should be investigated.
Reduction in Hospital Length of Stay for Patients Requiring Lower
Extremity Amputation
Joshua Unger, MD, Daniel Geersen, PAC, Nancy Payne, RN, Lu-Anne
Laws, CSW,Mary Jane Stillwagon, RN, Leila Mureebe, MDMPH, Cynthia
Shortell, MD. Duke University, Durham, NC
Objective(s): This study evaluated the effect of a multidisciplinary
approach and initiation of care pathways on hospital length of stay (LOS) for
lower extremity amputations.
Methods: Patients undergoing lower extremity amputations (toe,
below the knee, above the knee, or revision of prior amputation) between
January 2010 and December 2011 were retrospectively identified by
International Classification of Diseases–9th Edition codes (84.11, 84.12,
84.14, 84.15, or 84.3) in our institution’s administrative database after
obtaining Investigational Review Board approval. Midway through the
study period, in January 2011, a multidisciplinary change in care of these
patients was initiated. Among the changes made was initiation of twice-
weekly rounds with representatives from vascular surgery, limb loss
counseling, physical therapy, and a discharge coordinator. Patients’
discharge diagnoses and medical comorbidities were analyzed by All
Patient Refined Diagnosis Related Group (APR-DRG) in the University
HealthSystem Consortium (UHC) Clinical Database. LOS before and
after the change in practice was compared with similar patients in
academic institutions nationwide via the LOS index, defined as actual
LOS-to-expected LOS ratio.
Results: During the 2-year study period, 150 patients underwent 188
amputations, including 114 amputations in 2010. After the change in practice, 74
amputationswere performed in 2011. Patient demographicswere consistent across
the study period, including a72%prevalence of diabetesmellitus. AverageLOSwas
11.17.04days in 2010 anddecreased to9.616.37days in 2011 (P .0621),
without a significant change in readmission rate. The crude LOS decrease was not
statistically significant, but when adjusted for patient comorbidities, the LOS index
was significantly decreased from 1.19 0.629 in 2010 to 1.03 0.547 in 2011
(P .0365). LOS indexwas inversely related to the 30-day readmission rate (Fig).
Total savings to the hospital$150,000 for 2011.
Conclusions: A multidisciplinary partnership of physician and hos-
pital team members resulted in a decrease in LOS of 1.5 days for patients
undergoing lower extremity amputations, representing increased effi-
ciency of care and decreased observed costs.
Association of Inflammatory and Metabolic Serum Biomarkers With
Carotid Intima Media Thickness (cIMT) in a Community-Based Pop-
ulation: The Heart Strategies Concentrating on Risk Evaluation
(Heart SCORE) Study
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Objective(s):Carotid intimamedia thickness (cIMT) has been broadly
used as a surrogate measure for cardiovascular risk but is not widely available
or standardized. Our goal was to identify a set of serum biomarkers associ-
ated with cIMT independent of race and sex.
Methods: The Heart Strategies Concentrating on Risk Evaluation
(SCORE) study is a prospective community-based cohort study of 2000
adults that started enrollment in 2003. Serum biomarkers of inflammation,
metabolic, and endothelial function were obtained and examined in relation
to cIMT, which wasmeasured as a continuous variable and categorically with
a cutoff of 1 mm.
Results: cMIT was measured in 697 patients (66% white, 32% black;
62% women). Cohort demographics and comorbidities are detailed in the
Table. cIMT was positively associated with interleukin-6 (RS  0.17, P 
.0001), fasting glucose (RS 0.20, P .0001), and insulin (RS 0.14, P
.0002) levels and inversely associated with adiponectin (RS  0.20, P 
.0001), CD40L (RS  .014, P  .0003), and high-density lipoprotein
cholesterol (RS  0.20, P  .0001) levels. cIMT was not associated with
endostatin, highly-selective C-reactive protein, soluble intercellular adhe-
sion molecule, total cholesterol, low-density lipoprotein cholesterol, or
triglycerides. Multiple regression analysis identified age (partial correlation
[RP]  0.23, P  .0001), female sex (RP  0.16, P  .0001), black race
(RP  0.13, P  .0009), body mass index (RP  0.08, P  .04), serum
glucose (RP 0.14, P .0002), high-density lipoprotein cholesterol (RP
0.08, P  .03), and interleukin 6 (RP  0.07, P  .05) were indepen-
dently associated with cIMT.
Conclusions:We identified several biomarkers that are positively (interleu-
kin-6,glucose, insulin)or inversely (adiponectin,CD40L,high-density lipoprotein)
associated with cIMT. Because increased cIMT predicts cardiovascular outcomes,
examination of these clinical markers in relation to future cardiovascular events is
Fig.
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warranted to determine their role in risk stratification strategies.
Table. Patient characteristics
Variable No. (%) or mean (N  697)
Age group, years
44-55 206 (30)
56-65 336 (48)
66-74 155 (22)
Current smoker 48 (7)
Diabetes mellitus 49 (7)
Hypertension 261 (38)
Hyperlipidemia 330 (48)
Peripheral vascular disease 32 (4.7)
Stroke 13 (1.9)
Angiographic CAD 22 (3.47)
Body mass index, kg/m2 29.7
CAD, Coronary artery disease
Thrombospondin-1–Induced Vascular Smooth Muscle Cell Migration
Is Functionally Dependent on MicroRNA-21
Jeffrey J. Stein,1,2 Kristopher G. Maier, PhD,1,2 Vivian Gahtan, MD1,2.
1Department of Surgery, State University of New York Upstate Medical
University, and 2Department of Veteran Affairs Healthcare Network Up-
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Objective(s): Thrombospondin-1 (TSP-1) is a matricellular glyco-
protein released from platelets at sites of arterial injury. After angioplasty,
TSP-1 plays a role in the formation of the neointima. MicroRNAs (miR)
are small noncoding RNAs that traditionally function by binding target
gene messenger RNA and inhibiting protein translation. Previous study
has shown that miR-21 is upregulated after angioplasty, and inhibition of
miR-21 leads to decreased intimal hyperplasia. In this study, we exam-
ined the acute effects of miR-21 inhibition on vascular smooth muscle
cells (VSMCs).
Methods: Quiescent VSMCs were treated for 20 minutes with 25
nM miR-21 inhibitor. Migration toward TSP-1 (20 g/mL) or the
negative control, serum-free media (SFM) was assessed using a modified
Boyden microchemotaxis chamber. Quiescent VSMCs were acutely
treated with the miR-21 inhibitor and then exposed to TSP-1 or basal
media. Protein was collected, and phosphorylated extracellular signaling
kinase (pERK) 1/2 expression was assessed by Western blot. Densitom-
etry was converted to percent positive control. Quantitative real-time
polymerase chain reaction (qRT-PCR) for TSP-1, hyaluronic acid syn-
thase 2 (HAS2), and transforming growth factor-	2 (TGF-	2)was performed
on samples acutely treated with miR-21 inhibitor before a 6-hour exposure to
TSP-1. Statistical analysis was performedusing analysis of variancewith post hoc
testing. Significancewas set atP .05.Comparisons formigration andWestern
blots were made to positive control.
Results: TSP-1 increased VSMC migration compared with serum-free
media alone (100%  9.6% vs 43.7%  7.4%). miR-21 inhibitor treatment
reduced VSMCmigration to levels comparable to negative control (44.8%
4.9%). TSP-1 increased pERK 1/2 compared with basal media (p42:
100%  0% vs 78.6%  6.4%; p44: 100%  0% vs 76.2%  2.3%). miR-21
inhibition returned pERK to levels comparable with basal media (p42:
77%  6.2%; p44: 71%  9.8%). miR-21 inhibition had no effect on
TSP-1–stimulated expression of TSP-1, HAS2, or TGF-	2 (P  .05).
Conclusions: Acute inhibition of miR-21 leads to a functional
decrease in VSMC migration toward TSP-1. Additionally, acute inhibi-
tion of miR-21 decreased activated ERK 1/2, indicating a direct role for
miR-21 in the TSP-1 signaling cascade. However, miR-21 does not
acutely affect HAS2, TSP-1, or TGF-	2 gene expression. These data
indicate that miR-21 may directly modulate cell functions and signaling
pathways in ways other than by inhibition of protein translation.
Epigallocatechin-3-Gallate Is the Most Potent Phytochemical Inhibi-
tor of Experimental Intimal Hyperplasia in the Murine Carotid Artery
Vicente Orozco,MD,1 Rotem Naftalovich, BA,2 Dennis London,1 Daniel
Naftalovich,1 Eric Czernizer,1 Thomas Hoffman,1 Linsday Hessler, MD,1
Feng Quin, MD,1 Herbert Dardik, MD1. 1Division of Vascular Surgery,
Englewood Hospital and Medical Center, Englewood, NJ, and 2Robert
Wood Johnson School of Medicne, University of Medicine and Dentistry of
New Jersey, New Brunswick, NJ
Objective(s): This study evaluated the effect on intimal hyperplasia of
intraperitoneal (IP) administration of the phytochemicals resveratrol, allicin,
sulforaphane (SFN) and epigallocatechin-3-gallate (ECGC) in the murine
carotid artery injury model.
Methods: Myointimal hyperplasia (MIH) was induced in carotid ar-
teries of 27 rats by introduction of a wire with a diameter near that of the
artery (
0.2 mm.). The control group (n  5) was injected with saline,
whereas the experimental groups were injected daily with the corresponding
phytochemical. Intima-to-media ratios (IMR) were quantified on 2-week spec-
imens from photomicrographs using J software (National Institutes of Health,
Bethesda, MD). Statistical significance was measured by the Student t test.
Results: IP injections of phytochemical suppressed intimal hyperplasia in
rat carotid arteries at 2 weeks compared with controls and is summarized in the
Table. Further studies performed in the EGCG group consisted of Ki-67
proliferation indices and analysis of extracellular signal-regulated kinase, c-Jun
N-terminal kinases, and p-38 expression. Ki-67 index was significant reduced in
EGCG animals (3.3 1.0) compared with controls (6.2 1.3). Extracellular
signal-regulated kinase expression was similar suppressed in the EGCG group.
No change were noted for c-Jun N-terminal kinases and p-38 expression.
Conclusion: Intraperitoneal injection of the phytochemical ECGC has
significant suppressive effects on the development of myointimal hyperplasia in
our carotid artery injury model. Other phytochemicals showed lesser effects.
Table.
Study group
dose
Dose
(g) MIH (mm2)
Reduction
of control
(%) P IMR
Reduction
of control
(%) P
Control 0.22  0.03 0.70  0.08
Allicin 15 0.12  0.02 44 .05 0.41  0.05 40 .05
Resveratrol 18 0.09  0.03 50 .05 0.36  0.09 49 .05
Sulforaphane 0.48 0.09  0.03 57 .05 0.30  0.09 57 .01
EGCG 10 0.8  0.03 63 .05 0.20  0.05 72 .01
EGCG, Epigallocatechin-3-gallate; IMR, intima-to-media ratios; MIH,
myointimal hyperplasia.
Vascular Endothelial Growth Factor-A Inhibits Venous Marker Ex-
pression and Stimulates Arterial Marker Expression in Adult Venous
Endothelial Cells
Chenzi Yang,MD,1,2 Yuanyuan Guo, MD,2 Caroline C. Jadlowiec, MD,1
Clinton Protack, MD,1 Michael J. Collins, MD,1 Chang Shu, MD, PhD,2
Alan Dardik, MD, PhD1. 1Yale University, New Haven, Conn, and 2The
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China
Objective(s): Vascular endothelial growth factor (VEGF) stimulates
angiogenesis and determines arterial identity in embryonic endothelial
cells (ECs). When vein grafts are placed into arterial circulation, VEGF
expression transiently increases; yet, later time points find its expression
to be ultimately decreased. As such, the role of VEGF in normal vein graft
adaptation to the arterial environment is not clear, and its role in adult
EC phenotypic regulation remains unknown. Accordingly, we examined
the role of VEGF in modulating phenotypic changes in adult venous ECs.
Methods: Adult mouse lung endothelial cells (MLECs) were stimu-
lated with 100 ng/mL VEGF-A165 for 0 to 24 hours. In some experiments,
cells were pretreated for 1 hour with VEGF receptor 2 (R2) neutralization
antibody (1 g/mL) or VEGFR2 kinase inhibitor (100 nM) before
VEGF-A stimulation. EphB4, Ephrin-B2, delta-like ligand 4 (Dll4), neuro-
pilin-1, and neuropilin-2 expression were examined using real-time quanti-
tative polymerase chain reaction.
Results: At baseline, adult MLECs display a venous phenotype and are
EphB4-positive and Ephrin-B2-negative. VEGF treatment resulted in
downregulation of the venous marker EphB4 in a time-dependent (n  8,
P .0003) and dose-dependent (n 3, P .05) manner. VEGF treatment
increased expression of Dll4 in a time-dependent manner (n  8; P  .0001)
but did not affect Ephrin-B2 (n 8, P .05). Neruropilin-1 and neuropilin-2
expression were transiently increased at 1 hour and decreased by 24 hours (n
8; P .0001). Pretreatment with VEGFR2 neutralizing antibody or VEGFR2
kinase inhibitor inhibited EphB4 downregulation and the early increased ex-
pression of neuropilin-2 but did not affect the upregulation of Dll4 (n 3, P
.3276) nor the early increased expression of neuropilin-1.
Conclusions: In adult venous ECs, VEGF inhibits expression of ve-
nousmarker EphB4 and stimulates expression of arterial marker Dll4. VEGF
regulation of EphB4 is mediated by VEGFR2. Our results suggest that
regulation of Dll4 is independent of VEGFR2might be through an alternate
pathway. The finding that arterial marker Ephrin-B2 is not increased by
VEGF treatment is consistent with our prior work showing that vein graft
adaptation results in loss of venous EphB4 identity without a gain of arterial
Ephrin-B2 identity. Vein graft adaptation to the arterial environment may
depend on the plasticity of adult ECs and their ability to integrate VEGF
signaling pathways to properly modify vessel phenotype.
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